Laboratory products
TOC in pharma
Jun 11 2020
Author: Bernd Bletzinger, Product Manager TOC on behalf of Analytik Jena GmbH
To minimize or prevent cross contamination from product to product in pharmaceutical production equipment, manufacturers are obliged to establish defined cleaning processes in accordance with the pharmaceutical operating regulations. According to the ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, the effectiveness of these cleaning procedures is to be demonstrated regularly by the use of analytical measuring techniques. This means that after successful cleaning a check must be carried out for residues of active pharmaceutical ingredients (API), additives, detergents and their decomposition and reaction products, using a representative and validated sampling and analysis method. Both, substance-specific techniques (HPLC, GC, etc.), as well as non-specific analysis techniques (sum parameters TOC or TN) are used, other indicators are conductivity, pH and surface tension. Since each of the possible contaminants listed above typically represents organic compounds and can be addressed by total organic carbon, TOC has been chosen and pushed by the FDA to become the number one non-substance specific screening parameter in cleaning validation.
Additionally TOC determination is a mandatory parameter in WFI (water for injection) and AP (aqua purificata – purified water for pharmaceutical use) quality control and a well described pharmacopoeia method with ultralow detection limits below 50 ppb according to Pharm. Eur. 2.2.44 and USP monographs.
Digital Edition
Lab Asia 32.1 Feb 2025
February 2025
Chromatography Articles - Comparing volumetric and thermal flowmeters for assessing and validating liquid chromatography performance Mass Spectrometry & Spectroscopy Articles - The importa...
View all digital editions
Events
SPS Smart Production Solutions Guangzhou
Feb 25 2025 Guanghzou, China
Feb 25 2025 Amsterdam, Netherlands
Feb 27 2025 Kathmandu, Nepal
Mar 01 2025 Boston, MA, USA
Mar 02 2025 Bethesda, MD, USA